MEDICAMENT CONTAINING AN EFFECTOR OF THE GLUTATHIONE METABOLISM TOGETHER WITH ALPHA-LIPOIC ACID FOR IMMUNOMODULATION, IMMUNOSTIMULATION AND/OR ANTIPHLOGISTIC TREATMENT

A new medicament (A) for treating thiol-disulfide status disorders in diabetes mellitus comprises a glutathione metabolism effector (I) and alpha -lipoic acid (II) (both optionally in salt and/or prodrug form), as a combination preparation for simultaneous, separate or successive administration. Ind...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MICHAEL TAEGER, GERHARD FRIES, SIEGFRIED ANSORGE, DIETER KOEGST
Format: Patent
Sprache:eng ; por
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator MICHAEL TAEGER
GERHARD FRIES
SIEGFRIED ANSORGE
DIETER KOEGST
description A new medicament (A) for treating thiol-disulfide status disorders in diabetes mellitus comprises a glutathione metabolism effector (I) and alpha -lipoic acid (II) (both optionally in salt and/or prodrug form), as a combination preparation for simultaneous, separate or successive administration. Independent claims are also included for the use of (I) together with (II) for the preparation of a medicament for treating thiol-disulfide status disorders, as immunomodulator and/or defense mechanism stimulant or as antiinflammatory agent, all for combating diabetes mellitus. ACTIVITY : Antidiabetic; Immunomodulator; Antiinflammatory. MECHANISM OF ACTION : Thiol-disulfide status regulator; glutathione metabolism effector; Angiotensin converting enzyme (ACE) inhibitor; Antioxidant; Free radical scavenger. When peripheral immune cells were cultured under thiol-deficient conditions, optionally in presence of captopril (Ia) and/or (II), the intracellular thiol expression (in mfi(Beads/Ratio)) (initially 2.88) after 14 days was 0.65 in controls (without addition of (Ia) or (II)), 1.83 in presence of 50 MicroM (II), 0.75 in presence of 10 MicroM (Ia) or 2.86 in presence of 50 MicroM (II) plus 10 MicroM (Ia).
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PT1529529EE</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PT1529529EE</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PT1529529EE3</originalsourceid><addsrcrecordid>eNqNTkEKAjEQ24sHUf8wD1BExYPHsTttB9rOss7icVmknkQF_ZPftMI-QAgEkpBkWn0i1WwwUlIwkhQ5cXKACchaMiotiAX1BC50iupZEkEkxaMEPkVQcVTsFs6sHjA0HleBG2EDaLgGWxo4xi5JlLoLqKVgOSon5ThKZbFelygm5cYHcVxMA9oS6u_cvJpch9srL0aeVWBJjV_l56PPr-dwyff87hvd7LeHAqLdH5EvJ1VHeA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MEDICAMENT CONTAINING AN EFFECTOR OF THE GLUTATHIONE METABOLISM TOGETHER WITH ALPHA-LIPOIC ACID FOR IMMUNOMODULATION, IMMUNOSTIMULATION AND/OR ANTIPHLOGISTIC TREATMENT</title><source>esp@cenet</source><creator>MICHAEL TAEGER ; GERHARD FRIES ; SIEGFRIED ANSORGE ; DIETER KOEGST</creator><creatorcontrib>MICHAEL TAEGER ; GERHARD FRIES ; SIEGFRIED ANSORGE ; DIETER KOEGST</creatorcontrib><description>A new medicament (A) for treating thiol-disulfide status disorders in diabetes mellitus comprises a glutathione metabolism effector (I) and alpha -lipoic acid (II) (both optionally in salt and/or prodrug form), as a combination preparation for simultaneous, separate or successive administration. Independent claims are also included for the use of (I) together with (II) for the preparation of a medicament for treating thiol-disulfide status disorders, as immunomodulator and/or defense mechanism stimulant or as antiinflammatory agent, all for combating diabetes mellitus. ACTIVITY : Antidiabetic; Immunomodulator; Antiinflammatory. MECHANISM OF ACTION : Thiol-disulfide status regulator; glutathione metabolism effector; Angiotensin converting enzyme (ACE) inhibitor; Antioxidant; Free radical scavenger. When peripheral immune cells were cultured under thiol-deficient conditions, optionally in presence of captopril (Ia) and/or (II), the intracellular thiol expression (in mfi(Beads/Ratio)) (initially 2.88) after 14 days was 0.65 in controls (without addition of (Ia) or (II)), 1.83 in presence of 50 MicroM (II), 0.75 in presence of 10 MicroM (Ia) or 2.86 in presence of 50 MicroM (II) plus 10 MicroM (Ia).</description><language>eng ; por</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20090511&amp;DB=EPODOC&amp;CC=PT&amp;NR=1529529E$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20090511&amp;DB=EPODOC&amp;CC=PT&amp;NR=1529529E$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MICHAEL TAEGER</creatorcontrib><creatorcontrib>GERHARD FRIES</creatorcontrib><creatorcontrib>SIEGFRIED ANSORGE</creatorcontrib><creatorcontrib>DIETER KOEGST</creatorcontrib><title>MEDICAMENT CONTAINING AN EFFECTOR OF THE GLUTATHIONE METABOLISM TOGETHER WITH ALPHA-LIPOIC ACID FOR IMMUNOMODULATION, IMMUNOSTIMULATION AND/OR ANTIPHLOGISTIC TREATMENT</title><description>A new medicament (A) for treating thiol-disulfide status disorders in diabetes mellitus comprises a glutathione metabolism effector (I) and alpha -lipoic acid (II) (both optionally in salt and/or prodrug form), as a combination preparation for simultaneous, separate or successive administration. Independent claims are also included for the use of (I) together with (II) for the preparation of a medicament for treating thiol-disulfide status disorders, as immunomodulator and/or defense mechanism stimulant or as antiinflammatory agent, all for combating diabetes mellitus. ACTIVITY : Antidiabetic; Immunomodulator; Antiinflammatory. MECHANISM OF ACTION : Thiol-disulfide status regulator; glutathione metabolism effector; Angiotensin converting enzyme (ACE) inhibitor; Antioxidant; Free radical scavenger. When peripheral immune cells were cultured under thiol-deficient conditions, optionally in presence of captopril (Ia) and/or (II), the intracellular thiol expression (in mfi(Beads/Ratio)) (initially 2.88) after 14 days was 0.65 in controls (without addition of (Ia) or (II)), 1.83 in presence of 50 MicroM (II), 0.75 in presence of 10 MicroM (Ia) or 2.86 in presence of 50 MicroM (II) plus 10 MicroM (Ia).</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNTkEKAjEQ24sHUf8wD1BExYPHsTttB9rOss7icVmknkQF_ZPftMI-QAgEkpBkWn0i1WwwUlIwkhQ5cXKACchaMiotiAX1BC50iupZEkEkxaMEPkVQcVTsFs6sHjA0HleBG2EDaLgGWxo4xi5JlLoLqKVgOSon5ThKZbFelygm5cYHcVxMA9oS6u_cvJpch9srL0aeVWBJjV_l56PPr-dwyff87hvd7LeHAqLdH5EvJ1VHeA</recordid><startdate>20090511</startdate><enddate>20090511</enddate><creator>MICHAEL TAEGER</creator><creator>GERHARD FRIES</creator><creator>SIEGFRIED ANSORGE</creator><creator>DIETER KOEGST</creator><scope>EVB</scope></search><sort><creationdate>20090511</creationdate><title>MEDICAMENT CONTAINING AN EFFECTOR OF THE GLUTATHIONE METABOLISM TOGETHER WITH ALPHA-LIPOIC ACID FOR IMMUNOMODULATION, IMMUNOSTIMULATION AND/OR ANTIPHLOGISTIC TREATMENT</title><author>MICHAEL TAEGER ; GERHARD FRIES ; SIEGFRIED ANSORGE ; DIETER KOEGST</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PT1529529EE3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; por</language><creationdate>2009</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MICHAEL TAEGER</creatorcontrib><creatorcontrib>GERHARD FRIES</creatorcontrib><creatorcontrib>SIEGFRIED ANSORGE</creatorcontrib><creatorcontrib>DIETER KOEGST</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MICHAEL TAEGER</au><au>GERHARD FRIES</au><au>SIEGFRIED ANSORGE</au><au>DIETER KOEGST</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MEDICAMENT CONTAINING AN EFFECTOR OF THE GLUTATHIONE METABOLISM TOGETHER WITH ALPHA-LIPOIC ACID FOR IMMUNOMODULATION, IMMUNOSTIMULATION AND/OR ANTIPHLOGISTIC TREATMENT</title><date>2009-05-11</date><risdate>2009</risdate><abstract>A new medicament (A) for treating thiol-disulfide status disorders in diabetes mellitus comprises a glutathione metabolism effector (I) and alpha -lipoic acid (II) (both optionally in salt and/or prodrug form), as a combination preparation for simultaneous, separate or successive administration. Independent claims are also included for the use of (I) together with (II) for the preparation of a medicament for treating thiol-disulfide status disorders, as immunomodulator and/or defense mechanism stimulant or as antiinflammatory agent, all for combating diabetes mellitus. ACTIVITY : Antidiabetic; Immunomodulator; Antiinflammatory. MECHANISM OF ACTION : Thiol-disulfide status regulator; glutathione metabolism effector; Angiotensin converting enzyme (ACE) inhibitor; Antioxidant; Free radical scavenger. When peripheral immune cells were cultured under thiol-deficient conditions, optionally in presence of captopril (Ia) and/or (II), the intracellular thiol expression (in mfi(Beads/Ratio)) (initially 2.88) after 14 days was 0.65 in controls (without addition of (Ia) or (II)), 1.83 in presence of 50 MicroM (II), 0.75 in presence of 10 MicroM (Ia) or 2.86 in presence of 50 MicroM (II) plus 10 MicroM (Ia).</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; por
recordid cdi_epo_espacenet_PT1529529EE
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title MEDICAMENT CONTAINING AN EFFECTOR OF THE GLUTATHIONE METABOLISM TOGETHER WITH ALPHA-LIPOIC ACID FOR IMMUNOMODULATION, IMMUNOSTIMULATION AND/OR ANTIPHLOGISTIC TREATMENT
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T11%3A17%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MICHAEL%20TAEGER&rft.date=2009-05-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPT1529529EE%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true